UCB SA (OTCMKTS:UCBJF) Receives $114.88 Average Price Target from Analysts

Shares of UCB SA (OTCMKTS:UCBJFGet Rating) have been assigned an average recommendation of “Buy” from the ten research firms that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $114.88.

Several equities research analysts have recently commented on UCBJF shares. Deutsche Bank Aktiengesellschaft cut UCB to a “hold” rating and set a $95.00 target price for the company. in a research note on Monday, January 24th. UBS Group upgraded UCB from a “sell” rating to a “neutral” rating and set a $105.00 target price on the stock in a report on Wednesday, March 23rd. Cowen started coverage on UCB in a report on Friday, January 21st. They set an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded UCB from a “hold” rating to a “buy” rating and set a $123.00 target price on the stock in a report on Thursday, March 3rd.

OTCMKTS UCBJF opened at $122.90 on Friday. The stock has a fifty day moving average of $109.24 and a 200-day moving average of $110.78. UCB has a 52 week low of $93.00 and a 52 week high of $122.90. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.31 and a quick ratio of 1.00.

UCB Company Profile (Get Rating)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Featured Articles

Analyst Recommendations for UCB (OTCMKTS:UCBJF)

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.